JP2015508652A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508652A5 JP2015508652A5 JP2014557602A JP2014557602A JP2015508652A5 JP 2015508652 A5 JP2015508652 A5 JP 2015508652A5 JP 2014557602 A JP2014557602 A JP 2014557602A JP 2014557602 A JP2014557602 A JP 2014557602A JP 2015508652 A5 JP2015508652 A5 JP 2015508652A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding
- binding polypeptide
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009739 binding Methods 0.000 claims 53
- 229920001184 polypeptide Polymers 0.000 claims 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims 36
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 102100027287 Serpin H1 Human genes 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 11
- 101000836383 Homo sapiens Serpin H1 Proteins 0.000 claims 8
- 108010038679 colligin Proteins 0.000 claims 6
- 102000009027 Albumins Human genes 0.000 claims 3
- 108010088751 Albumins Proteins 0.000 claims 3
- 108091006027 G proteins Proteins 0.000 claims 2
- 102000030782 GTP binding Human genes 0.000 claims 2
- 108091000058 GTP-Binding Proteins 0.000 claims 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1250145 | 2012-02-20 | ||
| SE1250145-8 | 2012-02-20 | ||
| PCT/SE2013/050139 WO2013126006A1 (en) | 2012-02-20 | 2013-02-19 | Polypeptides binding to human complement c5 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017201509A Division JP6719438B2 (ja) | 2012-02-20 | 2017-10-18 | ヒト補体ｃ５に結合するポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508652A JP2015508652A (ja) | 2015-03-23 |
| JP2015508652A5 true JP2015508652A5 (enExample) | 2016-04-07 |
| JP6276202B2 JP6276202B2 (ja) | 2018-02-07 |
Family
ID=49006055
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014557602A Active JP6276202B2 (ja) | 2012-02-20 | 2013-02-19 | ヒト補体ｃ５に結合するポリペプチド |
| JP2017201509A Active JP6719438B2 (ja) | 2012-02-20 | 2017-10-18 | ヒト補体ｃ５に結合するポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017201509A Active JP6719438B2 (ja) | 2012-02-20 | 2017-10-18 | ヒト補体ｃ５に結合するポリペプチド |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US9808502B2 (enExample) |
| EP (3) | EP3511339B1 (enExample) |
| JP (2) | JP6276202B2 (enExample) |
| KR (2) | KR102149028B1 (enExample) |
| CN (1) | CN104114574B (enExample) |
| AU (3) | AU2013222836B2 (enExample) |
| BR (1) | BR112014020427B1 (enExample) |
| CA (1) | CA2863862C (enExample) |
| CY (1) | CY1121455T1 (enExample) |
| DK (1) | DK2817329T3 (enExample) |
| ES (1) | ES2715638T3 (enExample) |
| HR (1) | HRP20190522T1 (enExample) |
| HU (1) | HUE041996T2 (enExample) |
| IL (2) | IL234114B (enExample) |
| LT (1) | LT2817329T (enExample) |
| ME (1) | ME03640B (enExample) |
| MX (1) | MX359201B (enExample) |
| MY (1) | MY167232A (enExample) |
| NZ (1) | NZ628625A (enExample) |
| PH (1) | PH12014501604B1 (enExample) |
| PL (1) | PL2817329T3 (enExample) |
| PT (1) | PT2817329T (enExample) |
| RS (1) | RS58503B1 (enExample) |
| RU (1) | RU2654668C2 (enExample) |
| SG (1) | SG11201404942UA (enExample) |
| SI (1) | SI2817329T1 (enExample) |
| SM (1) | SMT201900189T1 (enExample) |
| TR (1) | TR201903840T4 (enExample) |
| UA (1) | UA117096C2 (enExample) |
| WO (1) | WO2013126006A1 (enExample) |
| ZA (1) | ZA201406773B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6276202B2 (ja) * | 2012-02-20 | 2018-02-07 | スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） | ヒト補体ｃ５に結合するポリペプチド |
| EP2912054B1 (en) * | 2012-10-25 | 2017-06-21 | Affibody AB | Albumin binding polypeptide |
| DK2912051T3 (en) | 2012-10-25 | 2018-06-14 | Affibody Ab | PROCEDURE FOR SEPARATION OF PROTEINS CONTAINING AN ALBUMIN BINDING DOMAIN |
| JP7138411B2 (ja) | 2013-08-28 | 2022-09-16 | アフィボディ・アーベー | 変異した骨格を有する結合ポリペプチド |
| PT3038633T (pt) * | 2013-08-28 | 2021-01-14 | Ipc Res Llc | Polipéptidos estáveis que se ligam ao complemento humano c5 |
| HUE055931T2 (hu) | 2014-06-12 | 2022-01-28 | Ra Pharmaceuticals Inc | A komplementaktivitás modulálása |
| JP7028557B2 (ja) * | 2014-06-13 | 2022-03-02 | アフィボディ アクティエボラーグ | 新規ポリペプチド |
| JP6678661B2 (ja) | 2014-06-13 | 2020-04-08 | アフィボディ アクティエボラーグ | 新規ポリペプチド |
| DE102014225439A1 (de) * | 2014-12-10 | 2016-06-16 | Zf Friedrichshafen Ag | Stufenplanet |
| CN108064235A (zh) * | 2015-01-12 | 2018-05-22 | 阿菲博迪公司 | Il-17a结合多肽 |
| US9937222B2 (en) | 2015-01-28 | 2018-04-10 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| AU2016370210A1 (en) * | 2015-12-16 | 2018-06-21 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| CN110087668A (zh) | 2016-12-07 | 2019-08-02 | Ra制药公司 | 补体活性的调节剂 |
| UY37651A (es) | 2017-03-31 | 2018-10-31 | Swedish Orphan Biovitrum Ab Publ | Polipéptido de unión al il-1r-i |
| KR20250068795A (ko) * | 2017-07-11 | 2025-05-16 | 알렉시온 파마슈티칼스, 인코포레이티드 | 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질 |
| WO2020198778A1 (en) | 2019-04-03 | 2020-10-08 | Clean Earth Technology Pty Ltd | Materials and processes for recovering precious metals |
| WO2021089695A1 (en) * | 2019-11-05 | 2021-05-14 | Affibody Ab | Polypeptides |
| CN116472065A (zh) * | 2020-10-05 | 2023-07-21 | 阿雷克森制药公司 | 治疗皮肌炎的方法 |
| WO2024227886A1 (en) | 2023-05-02 | 2024-11-07 | Mebrahtu Aman | Bispecific binding molecule |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5135916A (en) | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
| US6395888B1 (en) | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| CA2184356A1 (en) | 1994-03-03 | 1995-09-08 | Russell P. Rother | Terminal complement inhibitor fusion genes and proteins |
| US5627264A (en) | 1994-03-03 | 1997-05-06 | Alexion Pharmaceuticals, Inc. | Chimeric complement inhibitor proteins |
| ES2236706T3 (es) | 1994-03-23 | 2005-07-16 | Alexion Pharmaceuticals, Inc. | Procedimiento para reducir las disfunciones de los sistemas inmunitario y hemostatico durante la circulacion extracorporal. |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| DE69534701T2 (de) | 1994-09-23 | 2006-10-19 | Alexion Pharmaceuticals, Inc., Cheshire | Verfahren zur behandlung von entzündlichen gelenkerkrankungen |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| CA2424379C (en) | 2000-10-10 | 2013-10-01 | Tanox, Inc. | Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| BRPI0211953B8 (pt) | 2001-08-17 | 2021-05-25 | Genentech Inc | anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| JP2006507834A (ja) | 2002-12-02 | 2006-03-09 | レジステンティア ファーマシューティカルズ アーベー | 自己ｃ５アミノ酸セグメントおよび非自己アミノ酸セグメントを含むポリペプチドを用いて炎症状態を治療するための方法及び材料 |
| US7361339B2 (en) | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
| MXPA05012880A (es) | 2003-06-02 | 2006-02-22 | Evolutec Ltd | Inhibidores de complemento. |
| CA2579635A1 (en) | 2003-09-10 | 2005-03-17 | Baxter International Inc. | Peptides that inhibit complement activation |
| SE0400274D0 (sv) | 2004-02-09 | 2004-02-09 | Affibody Ab | New polypeptide |
| US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| EP1735334A4 (en) | 2004-03-24 | 2007-09-05 | Auckland Uniservices Ltd | SET1 PROTEINS AND APPLICATIONS THEREOF |
| WO2005097202A2 (en) | 2004-04-06 | 2005-10-20 | Affibody Ab | Use of serum albumin binding peptides conjugates for the preparation of a medicament |
| GB0518443D0 (en) * | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| KR20170002684A (ko) * | 2005-11-04 | 2017-01-06 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
| GB0524788D0 (en) | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
| SG172686A1 (en) | 2006-03-08 | 2011-07-28 | Archemix Corp | Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders |
| CA3022097C (en) * | 2006-03-15 | 2020-10-27 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| US20100119530A1 (en) | 2006-07-06 | 2010-05-13 | Wenchao Song | Regulation of TLR Signaling by Complement |
| US9388235B2 (en) | 2006-09-05 | 2016-07-12 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
| GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| SG174101A1 (en) * | 2006-09-08 | 2011-09-29 | Genentech Inc | Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders |
| EA200901211A1 (ru) * | 2007-03-22 | 2010-04-30 | Новартис Аг | Антигены белка с5 и их применение |
| US20100263061A1 (en) | 2007-06-11 | 2010-10-14 | The Trustees Of The University Of Pennsylvania | Properdin Modulation of Alternative Pathway and Uses Thereof |
| EP2190863B1 (en) | 2007-07-31 | 2015-09-02 | Affibody AB | New albumin binding compositions, methods and uses |
| WO2009030240A2 (en) | 2007-09-05 | 2009-03-12 | Immunobond Aps | Method of determining functional deficiencies in the complement system |
| EP2077272A1 (en) | 2007-12-21 | 2009-07-08 | Affibody AB | Polypeptide libraries with a predetermined scaffold |
| ES2373832T3 (es) | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| US9187535B2 (en) * | 2007-12-19 | 2015-11-17 | Affibody Ab | Polypeptide derived from protein A and able to bind PDGF |
| EP2072525A1 (en) | 2007-12-21 | 2009-06-24 | Affibody AB | New polypeptides having affinity for HER2 |
| PT2328616E (pt) * | 2008-08-05 | 2015-08-26 | Novartis Ag | Composições e métodos para anticorpos dirigidos à proteína c5 do complemento |
| AU2009313203B2 (en) | 2008-11-10 | 2015-08-27 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| EP2327725A1 (en) * | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
| MX2012010116A (es) | 2010-03-01 | 2013-02-26 | Alexion Pharma Inc | Metodos y composiciones para el tratamiento de la enfermedad de degos. |
| US20110250215A1 (en) * | 2010-04-02 | 2011-10-13 | Athena Discovery, Inc. | Structurally-related relaxin-fusion proteins with extended in vivo half-lives |
| EP2824111B1 (en) | 2010-04-30 | 2017-03-22 | Alexion Pharmaceuticals, Inc. | Anti-C5A Antibodies and Methods for Using the Antibodies |
| JP5827994B2 (ja) | 2010-07-09 | 2015-12-02 | アフィボディ・アーベー | ポリペプチド |
| EP2726103B1 (en) | 2011-07-01 | 2018-09-05 | The Trustees Of The University Of Pennsylvania | Anti-properdin antibodies and uses thereof |
| JP6276202B2 (ja) | 2012-02-20 | 2018-02-07 | スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） | ヒト補体ｃ５に結合するポリペプチド |
| CA2873511A1 (en) | 2012-05-17 | 2013-11-21 | Ra Pharmaceuticals, Inc. | Peptide and peptidomimetic inhibitors |
| JP5980104B2 (ja) | 2012-11-22 | 2016-08-31 | 三菱電機株式会社 | 液晶表示装置の製造方法および液晶表示装置の製造システム |
| EP2935335B1 (en) | 2012-12-19 | 2020-10-28 | Affibody AB | New polypeptides |
| MX366425B (es) | 2013-03-15 | 2019-07-04 | Affibody Ab | Nuevos polipeptidos. |
| PT3038633T (pt) | 2013-08-28 | 2021-01-14 | Ipc Res Llc | Polipéptidos estáveis que se ligam ao complemento humano c5 |
| JP7138411B2 (ja) | 2013-08-28 | 2022-09-16 | アフィボディ・アーベー | 変異した骨格を有する結合ポリペプチド |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
-
2013
- 2013-02-19 JP JP2014557602A patent/JP6276202B2/ja active Active
- 2013-02-19 SG SG11201404942UA patent/SG11201404942UA/en unknown
- 2013-02-19 AU AU2013222836A patent/AU2013222836B2/en active Active
- 2013-02-19 RS RS20190369A patent/RS58503B1/sr unknown
- 2013-02-19 SM SM20190189T patent/SMT201900189T1/it unknown
- 2013-02-19 SI SI201331358T patent/SI2817329T1/sl unknown
- 2013-02-19 WO PCT/SE2013/050139 patent/WO2013126006A1/en not_active Ceased
- 2013-02-19 KR KR1020147025537A patent/KR102149028B1/ko active Active
- 2013-02-19 PL PL13752233T patent/PL2817329T3/pl unknown
- 2013-02-19 NZ NZ628625A patent/NZ628625A/en unknown
- 2013-02-19 US US14/378,522 patent/US9808502B2/en active Active
- 2013-02-19 EP EP18213025.2A patent/EP3511339B1/en active Active
- 2013-02-19 MX MX2014009879A patent/MX359201B/es active IP Right Grant
- 2013-02-19 EP EP13752233.0A patent/EP2817329B1/en active Active
- 2013-02-19 UA UAA201409807A patent/UA117096C2/uk unknown
- 2013-02-19 RU RU2014137303A patent/RU2654668C2/ru active
- 2013-02-19 ME MEP-2019-84A patent/ME03640B/me unknown
- 2013-02-19 DK DK13752233.0T patent/DK2817329T3/en active
- 2013-02-19 LT LTEP13752233.0T patent/LT2817329T/lt unknown
- 2013-02-19 HR HRP20190522TT patent/HRP20190522T1/hr unknown
- 2013-02-19 CN CN201380009789.0A patent/CN104114574B/zh active Active
- 2013-02-19 ES ES13752233T patent/ES2715638T3/es active Active
- 2013-02-19 TR TR2019/03840T patent/TR201903840T4/tr unknown
- 2013-02-19 EP EP25168811.5A patent/EP4616914A3/en active Pending
- 2013-02-19 KR KR1020207024244A patent/KR102336895B1/ko active Active
- 2013-02-19 PT PT13752233T patent/PT2817329T/pt unknown
- 2013-02-19 MY MYPI2014702257A patent/MY167232A/en unknown
- 2013-02-19 BR BR112014020427-6A patent/BR112014020427B1/pt active IP Right Grant
- 2013-02-19 CA CA2863862A patent/CA2863862C/en active Active
- 2013-02-19 HU HUE13752233A patent/HUE041996T2/hu unknown
-
2014
- 2014-07-11 PH PH12014501604A patent/PH12014501604B1/en unknown
- 2014-08-13 IL IL234114A patent/IL234114B/en active IP Right Grant
- 2014-09-16 ZA ZA2014/06773A patent/ZA201406773B/en unknown
-
2017
- 2017-09-29 US US15/721,507 patent/US10206975B2/en active Active
- 2017-10-12 AU AU2017245376A patent/AU2017245376B2/en active Active
- 2017-10-18 JP JP2017201509A patent/JP6719438B2/ja active Active
-
2018
- 2018-12-20 US US16/228,181 patent/US11123401B2/en active Active
-
2019
- 2019-03-20 CY CY20191100331T patent/CY1121455T1/el unknown
- 2019-06-30 IL IL267724A patent/IL267724B/en unknown
- 2019-10-18 AU AU2019250239A patent/AU2019250239B2/en active Active
-
2021
- 2021-09-20 US US17/479,101 patent/US12083160B2/en active Active
-
2024
- 2024-09-09 US US18/828,700 patent/US20250332214A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015508652A5 (enExample) | ||
| RU2014137303A (ru) | Полипептиды, связывающиеся с компонентом с5 системы комплемента человека | |
| JP2012082206A5 (enExample) | ||
| JP2010534486A5 (enExample) | ||
| JP2017524380A5 (ja) | 腫瘍血管遮断剤であるポリペプチド、遺伝子、発現ベクター、腫瘍血管遮断剤の組成物、及び腫瘍血管遮断剤であるポリペプチドの調製方法 | |
| JP2016052315A5 (enExample) | ||
| JP2013509861A5 (enExample) | ||
| JP2006149365A5 (enExample) | ||
| JP2016034981A5 (enExample) | ||
| JP2016000731A5 (enExample) | ||
| JP2015527302A5 (enExample) | ||
| JP2015501656A5 (enExample) | ||
| JP2010189394A5 (enExample) | ||
| JP2020172505A5 (enExample) | ||
| JP2013027391A5 (enExample) | ||
| JP2013534812A5 (enExample) | ||
| RU2017134456A (ru) | Рекомбинантные связывающие белки и их применение | |
| RU2012153218A (ru) | Пептиды, проникающие в клетки, и их применения | |
| JP2014511698A5 (enExample) | ||
| JP2018537087A5 (enExample) | ||
| JP2018511327A5 (enExample) | ||
| JP2012115277A5 (enExample) | ||
| JP2013538864A5 (enExample) | ||
| MY162564A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| JP2013513377A5 (enExample) |